Senate Appropriations Committee Approves FY2024 Funding for CDMRP
July 28, 2023
Yesterday, by an overwhelming bipartisan vote of 27-1, the Senate Committee on Appropriations approved its version of the fiscal year 2024 Defense Appropriations Act. This legislation provides funding for the Congressionally Directed Medical Research Program (CDMRP) consistent with levels provided in previous years by the Committee. Specifically, the bill provides funding for a number of cancer programs, including breast cancer ($130 million), prostate cancer ($75 million), ovarian cancer ($15 million), and rare cancers ($17.5 million). While some of the cancer programs were proposed for cuts below the fiscal year 2023 levels, they will likely be restored in conference to their previous levels as proposed in the House version of the Defense Appropriations Act.
The Senate version of the bill also provides $370 million for the Peer Reviewed Medical Research Program, the same as appropriated in FY23, for 47 eligible conditions. The bill also flat maintains the Peer Reviewed Cancer Research Program at $130 million.
The Senate bill will likely come to the Senate floor in December. Meanwhile, the House bill’s floor fate has yet to be determined. However, in past years, Congress has found a way to enact a Defense Appropriations Act, and typically provides the higher levels of funding for programs where there are discrepancies between the House and Senate versions.
A summary of the bill is available HERE.
Bill text, as amended is available HERE.
The bill report, as amended, is available HERE.
Adopted amendments are available HERE.
